The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Phase III RUBY trial demonstrates potential of Jemperli + chemo to redefine treatment of advanced or recurrent endometrial cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In the phase III RUBY clinical trial, the Jemperli regimen showed a statistically significant and clinically meaningful improvement in progression free survival in the mismatch repair deficient/microsatellite instability-high population and in the overall population. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. 
Drugs & Targets

FDA grants breakthrough designation for Rina-S in advanced endometrial cancer

The FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S), an investigational folate receptor alpha-directed, TOPO1-inhibitor antibody-drug conjugate, for the treatment of adult patients with recurrent or progressive endometrial cancer who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy. 
Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account